Bli medlem
Bli medlem

Du är här

2020-08-06

AroCell initiates a clinical study in prostate cancer with University of Rome la Sapienza

AroCell announces today a new collaboration with the University of Rome la Sapienza to evaluate the role of TK1 and PSA as response biomarkers after hormone treatment in castration-resistant prostate cancer patients.

In the study TK1 protein levels will be measured in serum samples using AroCell TK 210 ELISA. Serum samples will be collected from 50 patients with an advanced metastatic prostate cancer diagnosis and 40 healthy controls. TK1 and PSA will be measured at the time of the diagnosis and 1, 3, and 6 months after the start of treatment. The objective is to help clinicians obtain more information by measuring the TK1 as a responsive biomarker in castration-resistant metastatic prostate cancer patients treated with hormone therapy.
 
The study will be executed in collaboration with Dr. Emanuela Anastasi at the Department of Molecular Medicine, University of Rome la Sapienza, Italy.
 
“We are excited to collaborate with University of Rome la Sapienza”, says Michael Brobjer, CEO of AroCell. “The AroCell TK 210 ELISA kit is a cost-efficient way to improve the monitoring of subjects with prostate cancer via a simple blood test, reducing costs and morbidity and improving patient’s quality of life”.

Contacts


Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About Thymidine Kinase 1


Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is up-regulated during the S phase of the cell cycle and degraded in mitosis. Its presence in cells indicates active cell proliferation. Increased levels of TK1 in the blood can indicate abnormal cell turnover or disruption of cells in active proliferation triggered by, for example, therapeutic agents.

About TK 210 ELISA


AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About University of Rome la Sapienza


University of Rome la Sapienza is a research university in Rome, Italy, and is one of the largest in Europe.

About AroCell


AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments


AroCell initiates a clinical study in prostate cancer with University of Rome la Sapienza

Författare AroCell

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.